CA2164119A1 - Derives de substitution en 1 d'isatine et d'oxindole, inhibiteurs de l'acetylcholinesterase - Google Patents

Derives de substitution en 1 d'isatine et d'oxindole, inhibiteurs de l'acetylcholinesterase

Info

Publication number
CA2164119A1
CA2164119A1 CA002164119A CA2164119A CA2164119A1 CA 2164119 A1 CA2164119 A1 CA 2164119A1 CA 002164119 A CA002164119 A CA 002164119A CA 2164119 A CA2164119 A CA 2164119A CA 2164119 A1 CA2164119 A1 CA 2164119A1
Authority
CA
Canada
Prior art keywords
lower alkyl
ethyl
compound
indol
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002164119A
Other languages
English (en)
Inventor
Bernard Robin Boar
Dennis Mark O'shea
Ian David Tomlinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2164119A1 publication Critical patent/CA2164119A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention se rapporte à de nouveaux composés ayant la formule générale (I) dans laquelle n vaut 3, 4, 5, 6 ou 7; X représente un ou plusieurs substituants sélectionnés indépendamment parmi hydrogène, alkyle inférieur, aryle, alcoxy inférieur, halogène, trifluorométhyle, nitro, -NHCOR où R représente alkyle inférieur ou aryle, -NR1R2 où R1 et R2 représentent indépendamment hydrogène ou alkyle inférieur ou forment un anneau, ou cycloalkyle, cycloalcényle ou bicycloalkyle, l'un et l'autre éventuellement également substitués par alkyle inférieur; Y représente (a) ou (b) où R<3> et R<4> représentent indépendamment hydrogène, alkyle inférieur, alcoxy inférieur ou forment un acétal cyclique; Z représente alkyle inférieur; et W représente un ou plusieurs substituants indépendamment sélectionnés parmi hydrogène, alkyle inférieur, alcoxy inférieur ou halogène; l'invention se rapporte également à des stéréo-isomères et à des isomères optiques et des racémates de ces composés dans lesquels ces isomères existent, ainsi qu'à des sels d'addition d'acide pharmaceutiquement acceptables de ceux-ci et à des solvates de ceux-ci ayant une activité thérapeutique, à leurs intermédiaires de préparation, à leurs procédés de préparation, aux formulations pharmaceutiques contenant ces composés et à l'utilisation médicinale de ces composés.
CA002164119A 1993-06-16 1994-05-13 Derives de substitution en 1 d'isatine et d'oxindole, inhibiteurs de l'acetylcholinesterase Abandoned CA2164119A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9302080-8 1993-06-16
SE19939302080A SE9302080D0 (sv) 1993-06-16 1993-06-16 New compounds

Publications (1)

Publication Number Publication Date
CA2164119A1 true CA2164119A1 (fr) 1994-12-22

Family

ID=20390305

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002164119A Abandoned CA2164119A1 (fr) 1993-06-16 1994-05-13 Derives de substitution en 1 d'isatine et d'oxindole, inhibiteurs de l'acetylcholinesterase

Country Status (9)

Country Link
EP (1) EP0703901A1 (fr)
JP (1) JPH08511515A (fr)
AU (1) AU7010894A (fr)
CA (1) CA2164119A1 (fr)
FI (1) FI956074A (fr)
IS (1) IS4167A (fr)
NO (1) NO955074L (fr)
SE (1) SE9302080D0 (fr)
WO (1) WO1994029272A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103752D0 (sv) * 1991-12-18 1991-12-18 Astra Ab New compounds
WO1999044608A1 (fr) * 1998-03-06 1999-09-10 Astrazeneca Ab Nouvelle utilisation
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
KR100639543B1 (ko) 1998-09-30 2006-10-31 다케다 야쿠힌 고교 가부시키가이샤 방광 배출력 개선제
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
JP2004529110A (ja) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
ATE440826T1 (de) 2004-05-27 2009-09-15 Ucb Pharma Sa Benzoxazolonderivate, verfahren zu deren herstellung und deren anwendungen
JP4897679B2 (ja) 2004-07-22 2012-03-14 ユセベ ファルマ ソシエテ アノニム インドロン誘導体、その製造方法及びその使用
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
WO2010090680A1 (fr) * 2008-12-15 2010-08-12 Wyeth Llc Agonistes de cb2 de type oxindole substitué
EP2533645B1 (fr) 2010-02-09 2016-07-27 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
GEP201706739B (en) 2012-12-13 2017-09-25 H Lundbeck As Compositions comprising vortioxetine and donepezil
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
EP2968237A4 (fr) 2013-03-15 2016-08-31 Univ Johns Hopkins Procédés et compositions pour améliorer la fonction cognitive
CN104530065A (zh) * 2013-05-13 2015-04-22 江西科技师范大学 1-n酰基取代吲哚酮衍生物的应用
CN103242332B (zh) * 2013-05-13 2015-11-04 江西科技师范大学 1-n酰基取代吲哚酮衍生物
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH491106A (de) * 1964-06-11 1970-05-31 Ciba Geigy Verfahren zur Herstellung von neuen Thiosemicarbazonen

Also Published As

Publication number Publication date
EP0703901A1 (fr) 1996-04-03
FI956074A0 (fi) 1995-12-18
JPH08511515A (ja) 1996-12-03
NO955074L (no) 1996-02-07
WO1994029272A1 (fr) 1994-12-22
IS4167A (is) 1994-12-17
SE9302080D0 (sv) 1993-06-16
AU7010894A (en) 1995-01-03
NO955074D0 (no) 1995-12-14
FI956074A (fi) 1995-12-18

Similar Documents

Publication Publication Date Title
CA2164119A1 (fr) Derives de substitution en 1 d&#39;isatine et d&#39;oxindole, inhibiteurs de l&#39;acetylcholinesterase
TWI251590B (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
JP3148253B2 (ja) ベンゾフリル誘導体類及びそれらの用途
EP0370901B1 (fr) Nouveaux dérivés du chromanne actifs sur le système nerveux central, leur procédé de préparation et les compositions pharmaceutiques en contenant
EP0624156A1 (fr) Derives d&#39;isatine, procedes de preparation, et composition pharmaceutique les contenant
WO2008000951A2 (fr) Dérivés d&#39;urees de tropane, leur préparation et leur application en thérapeutique
CZ391091A3 (en) Crystalline paroxetin hydrochloride hemihydrate, process for producing thereof and pharmaceutical preparations in which it is comprised
JPH07228558A (ja) スチルベン誘導体及びそれを含有する制癌剤
JPH0219112B2 (fr)
HU186933B (en) Process for producing 1-subsituted spiro-square bracket-piperidino-benzoxazine-square bracket closed derivatives and pharmaceutical compositions containing them
NO316913B1 (no) Benzotiadiazoler og derivater
EP1567150B1 (fr) Derives d indole-3-carboxamide, leur preparation et leur application en therapeutique
WO2023002005A1 (fr) Procédé de préparation d&#39;un dérivé de tryptamine
RU2232755C2 (ru) Производные пиридазин-3-она и содержащие их лекарственные средства
JPH0471072B2 (fr)
CA2378628C (fr) Nouveaux derives d&#39;indenoindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
LU86421A1 (fr) Derives de piperazine 1,4-disubstitues,composition pharmaceutique les contenant;leur procede d&#39;obtention
JP4548884B2 (ja) ４，５，６，７−テトラヒドロチエノ〔２，３−ｃ〕ピリジン誘導体
FR2902791A1 (fr) Derives d&#39;urees de tropane,leur preparation et leur application en therapeutique
JP3213324B2 (ja) 新規なｎ−ベンゾイルメチル−ピペリジン類
CA2557942C (fr) Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique
FR2753970A1 (fr) Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
CA2376876C (fr) Nouveaux derives d&#39;isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP3093170B2 (ja) ヒドロキノン誘導体及びその医薬用途
JP3999861B2 (ja) 新規ピリダジン誘導体及びこれを有効成分とする医薬

Legal Events

Date Code Title Description
FZDE Dead